Spent Under ₹10cr On Promo, Says Dolo 650 Maker

Mumbai : Micro Labs, manufacturer of Dolo 650, which is in the eye of a storm over alleged unethical practices, says it spent a minuscule amount — under Rs 10 crore per year — on the brand’s marketing and promotion.

The Bangalore-based firm, charged with distributing freebies of about Rs 1,000 crore to doctors, came under the scanner last week during a hearing in another case by the Federation of Medical and Sales Representatives Association in the Supreme Court. The Rs 2 pill became a household name for pain and fever relief during the pandemic, netting sales of Rs 362 crore for the year ended March this year — a growth of nearly 30%.

“Dolo 650 is a mega brand due to first-mover advantage, its quality, availability and reach across the country. It is a mass brand and an established market leader with 50% share, even before Covid,” Micro Labs CMD Dilip Surana told TOI, speaking for the first time on the issue.

Last month, the tax department searched the premises and conducted country-wide raids on offices of the Rs 4,500-crore Micro Labs on charges of alleged tax evasion. The company has spent Rs 1,000 crore as cumulative marketing expenditure across all brands, and not just on Dolo 650.

Executive VP (marketing) Jayaraj Govindaraju said, “On the pain relief pill alone the marketing expenditure has been typically 4-5% of its annual turnover of Rs 200-250 crore.” The basic promotions (to doctors) during Covid were of low value and included giving out free (Dolo) samples, brand reminders, masks & sanitizers, and scientific dissemination through conferences on fever, he added.

  • Related Posts

    AbbVie loses patent plea for Hep C drug

    New Delhi: The Indian Patent Office has refused to grant a secondary patent to AbbVie for its blockbuster Hepatitis C drug combination glecaprevir/pibrentasvir, sold globally under the brand name Maviret.…

    GSK’s Calpol a well-known trademark: High Court

    New Delhi: In a relief to UK-headquartered GlaxoSmithKline Pharmaceuticals (GSK), the Delhi High Court has declared its pain and fever medicine ‘Calpol’ as a well-known trademark that has acquired extensive…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    AbbVie loses patent plea for Hep C drug

    AbbVie loses patent plea for Hep C drug

    GSK’s Calpol a well-known trademark: High Court

    GSK’s Calpol a well-known trademark: High Court

    3 arrested for allegedly posing as doctors using forged MBBS degrees

    3 arrested for allegedly posing as doctors using forged MBBS degrees

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer